These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 37783154)
1. Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ. Zhang M; Barroso E; Ruart M; Peña L; Peyman M; Aguilar-Recarte D; Montori-Grau M; Rada P; Cugat C; Montironi C; Zarei M; Jurado-Aguilar J; Camins A; Balsinde J; Valverde ÁM; Wahli W; Palomer X; Vázquez-Carrera M Biomed Pharmacother; 2023 Nov; 167():115623. PubMed ID: 37783154 [TBL] [Abstract][Full Text] [Related]
2. Elafibranor interrupts adipose dysfunction-mediated gut and liver injury in mice with alcoholic steatohepatitis. Li TH; Yang YY; Huang CC; Liu CW; Tsai HC; Lin MW; Tsai CY; Huang SF; Wang YW; Lee TY; Huang YH; Hou MC; Lin HC Clin Sci (Lond); 2019 Feb; 133(3):531-544. PubMed ID: 30602573 [No Abstract] [Full Text] [Related]
3. Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice. Tsai HC; Chang FP; Li TH; Liu CW; Huang CC; Huang SF; Yang YY; Lee KC; Hsieh YC; Wang YW; Lee TY; Huang YH; Hou MC; Lin HC Biomed Res Int; 2019; 2019():6740616. PubMed ID: 31321239 [TBL] [Abstract][Full Text] [Related]
4. Insights into the Role of PPARβ/δ in NAFLD. Chen J; Montagner A; Tan NS; Wahli W Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29954129 [TBL] [Abstract][Full Text] [Related]
5. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease. Zarei M; Barroso E; Palomer X; Dai J; Rada P; Quesada-López T; Escolà-Gil JC; Cedó L; Zali MR; Molaei M; Dabiri R; Vázquez S; Pujol E; Valverde ÁM; Villarroya F; Liu Y; Wahli W; Vázquez-Carrera M Mol Metab; 2018 Feb; 8():117-131. PubMed ID: 29289645 [TBL] [Abstract][Full Text] [Related]
6. Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery. Boeckmans J; Gatzios A; Heymans A; Rombaut M; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM Cells; 2022 Mar; 11(5):. PubMed ID: 35269515 [TBL] [Abstract][Full Text] [Related]
7. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters. Briand F; Maupoint J; Brousseau E; Breyner N; Bouchet M; Costard C; Leste-Lasserre T; Petitjean M; Chen L; Chabrat A; Richard V; Burcelin R; Dubroca C; Sulpice T Metabolism; 2021 Apr; 117():154707. PubMed ID: 33444606 [TBL] [Abstract][Full Text] [Related]
8. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204 [TBL] [Abstract][Full Text] [Related]